Business Wire

EXCHANGER-INDUSTRIES

Share
Exchanger Industries Limited Acquires HRS Heat Exchangers

Exchanger Industries Limited (“EIL”), the Canadian market leader and globally recognized designer and manufacturer of heat transfer products for the energy, petrochemical, industrial and clean power generation sectors, has acquired HRS Heat Exchangers Ltd. ("HRS"). Financial terms were not disclosed.

HRS is widely recognized as the pre-eminent, international specialist supplier of heat exchangers and custom process systems across the environmental, food, beverage, and pharmaceutical sectors. The seasoned HRS management team will be retained by EIL and play a critical role in executing plans for robust international expansion afforded by the strategic combination of two distinct, yet complementary industry leaders.

“For decades, we’ve worked hard on behalf of our customers in Canada, the U.S. and 25 countries worldwide, consistently providing them with mission-critical, innovative solutions in some of the most demanding environments,” stated Mark el Baroudi, EIL’s CEO. “The HRS acquisition will provide numerous benefits to our customers including a broader capability to provide heat transfer solutions to environmentally sustainable projects in the biogas and wastewater treatment sectors, in addition to EIL’s existing projects in clean power generation, Liquified Natural Gas (LNG), emissions-free power storage and biofuels applications.”

To deliver these projects competitively, the acquisition provides EIL immediate access to a cost-effective global footprint with scalable hubs in both India and Spain, and a combined portfolio of anti-fouling technologies that enhances differentiation and acts as a unique platform to create value for customers.

Additionally, el Baroudi stated that the acquisition of HRS Heat Exchangers provides EIL an extraordinary opportunity to expand their exposure to an impressive international customer base across rapidly growing geographic market positions in the U.S., U.K., Spain, Mexico, India, the Middle East, Malaysia, Australia and New Zealand. As evidence of this opportunity, HRS was ranked number 161 in U.K.’s prestigious Sunday Times HSBC international top league table that tracks the international growth of U.K. based companies.

“We’re thrilled to join the EIL family and continue our journey to building a highly respected global supplier of heat transfer products,” added Steven Pither, founder and CEO of HRS. “Leveraging EIL’s expertise in designing innovative heat transfer systems and their established track record in creating streamlined, highly efficient business processes will allow us to enhance our product offering and effectively scale our Spanish and Indian manufacturing operations, delivering timely, cost effective solutions to our customer base around the world. We are confident that this will drive growth to the next level.”

“Our combined manufacturing capability and leading-edge product technologies will strengthen our value proposition and increase market penetration internationally,” said el Baroudi. “In short, this acquisition combines the capabilities of both parties to enhance an already differentiated market position. It creates better outcomes for everyone we serve.”

About Exchanger Industries Limited

Founded in Alberta Canada in 1961, Exchanger Industries Limited has more than sixty years of experience in the engineering, design, fabrication, and servicing of heat transfer solutions for the most demanding, mission critical applications. Serving customers across Canada and in 25 countries around the world, EIL’s mission is to provide cost effective investment and operating solutions through the practical application of heat transfer solutions in a wide variety of situations. EIL employs the best people in the industry and uses leading edge technologies, resulting in price-competitive solutions that are more energy efficient, long lasting and which minimize maintenance and downtime. For more information, visit www.exchangerindustries.com .

About HRS Heat Exchangers Limited

Founded in 1981, the HRS Group operates at the forefront of thermal technology, offering innovative and effective heat transfer products worldwide with a strong focus on managing energy efficiently. The company offers plate heat exchangers, corrugated tube heat exchangers (annular space heat exchangers, double tube heat exchangers, multitube heat exchangers) and scraped surface heat exchangers. HRS products and systems are used in HEVAC, food processing, chemical, pharmaceutical, water and energy industries, waste management and environmental protection. In 2019, HRS was ranked number 161 in the U.K.’s prestigious International Track 200 League Table. For more information, visit https://www.hrs-heatexchangers.com/ .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

TRU Simulation’s Bell 525 Flight Simulator Receives FAA Interim Level C Qualification17.11.2025 09:00:00 CET | Press release

TRU Simulation + Training Inc., a Textron Inc. (NYSE:TXT) company, and an affiliate of Textron Aviation Inc. and Bell Textron Inc. today announced its Bell 525 Full Flight Simulator (FFS) located at the Bell Training Academy received Interim Level C qualification from the Federal Aviation Administration (FAA). Bell Textron Inc. has designed and will manufacture the Bell 525 helicopter. By achieving this milestone, pilots can earn more flight hours on the Bell 525 platform ahead of the rotorcraft’s expected FAA type certification. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117520706/en/ TRU Simulation’s Bell 525 Flight Simulator receives FAA Interim Level C qualification “The accuracy and realism of our Flight Simulation Devices play a crucial role in ensuring that pilots can effectively translate their training into real-world scenarios,” said Jerry Messaris, vice president and general manager, TRU Simulation. “This q

Polpharma Biologics Confirms U.S. Launch of Tyruko® (natalizumab), the First and Only Biosimilar for Multiple Sclerosis17.11.2025 08:52:00 CET | Press release

Polpharma Biologics, a biopharmaceutical company group focused on biosimilars development and manufacturing, today confirmed that Sandoz Tyruko® (natalizumab-sztn) is now available to patients in the United States. Tyruko® is the first and only FDA-approved biosimilar of natalizumab for the treatment of relapsing forms of multiple sclerosis (MS), and also for adult patients with moderately to severely active Crohn’s disease1. Tyruko® was developed by Polpharma Biologics and will be commercialized in the U.S. by its collaboration partner Sandoz, under an exclusive global license agreement. The launch marks a significant milestone in expanding access to high-quality, affordable treatment options for patients living with MS and Crohn’s disease in the United States. Emmanuelle Lepine, Chair of the Supervisory Board, Polpharma Biologics, commented: "The U.S. launch of Tyruko® marks a pivotal moment not only for Polpharma Biologics, but for patients across the United States. This milestone r

Lone Star Acquires Multi-Asset Real Estate Portfolio from St. James’s Place17.11.2025 08:01:00 CET | Press release

Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Real Estate Fund VII, L.P. has successfully completed the acquisition of a multi-asset real estate portfolio from St. James’s Place (SJP) and its Property Unit Trust and Life and Pensions Trust. SJP was advised by Invesco Real Estate, the global real estate investment manager, on the sale of the portfolio. The portfolio comprises 16 high-quality assets across the UK, including multi-let industrial (“MLI”), retail, and office properties. The largest component is the MLI portfolio, which consists of 10 separate property assets predominantly located in Greater London and South East England, and offering access to major transportation and industrial hubs — making them highly attractive for last-mile delivery and regional distribution. The office properties are all situated in London, while the retail assets consist of high-quality retail warehouses with strong tenant bases. Lone Star will implement an active asset

Bureau Veritas appoints Santiago Arias Duval as Executive Vice-President for the Americas region17.11.2025 08:00:00 CET | Press release

Bureau Veritas, a global leader in Testing, Inspection and Certification (TIC), is pleased to announce the appointment of Santiago Arias Duval, effective November 17th, 2025, as Executive Vice-President, Americas. This appointment is in line with Bureau Veritas’ new operating model effective since September 1st, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251116192035/en/ Hinda Gharbi, CEO at Bureau Veritas Bureau Veritas is evolving the structure of its executive committee to drive greater organizational alignment. This organization will empower the regions with scalable Product Lines, enabling global solutions development, and will be unlocking wider cross-selling opportunities. The Americas region is created to leverage fast developing market opportunities across countries in North, Central and South America. This is a dynamic region for all Bureau Veritas where the group intends to expand its leadership across p

Incyte Announces Positive CHMP Opinion for Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma (FL)17.11.2025 07:00:00 CET | Press release

Pending the European Commission decision, Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide will represent an important new therapeutic option from second line for patients with follicular lymphoma (FL) in EuropeIn Western countries, relapsed or refractory FL affects 2-4 out of every 100,000 people1The positive Committee for Medicinal Products for Human Use (CHMP) recommendation is based on data from the Phase 3 inMIND trial which showed patients with relapsed or refractory FL achieved significantly improved progression-free survival with Minjuvi in combination with rituximab and lenalidomide2 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Minjuvi® (tafasitamab) in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) (Grade 1-3a) after at

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye